Get the latest tech news
Orakl Oncology combines data and biology to bring new drugs to cancer patients
Cancer incidence is on the rise, particularly among younger adults, but most new drug compounds fail to progress through clinical trials. According to
Founded in 2023 as a spinoff from the Gustave Roussy Institute of Oncology, Orakl operates at the intersection of data and biology, which makes it different from companies that only do one or the other, and more akin to Tempus, the AI healthtech that went public earlier this year. As for the data layer, it includes some 40 variables per patient, which makes up for the fact that its corpus is still smaller compared to its larger competitors, and with an initial focus on colorectal and pancreatic cancers. With this basis in place, Orakl plans to commercialize two products: O-Predict, which helps customers forecast patient response to a drug candidate, and O-Validate, where the process goes the other way around.
Or read this on TechCrunch
